anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Postoperative intra-abdominal infection is one of the most serious complications after pancreatic resection. Once diagnosed as postoperative intra-abdominal infection, the patient would not only suffer a lot, but also spend much more money and time in hospital. Moreover, subsequent sepsis and septic shock would imperil the patient's life. The preventive use of antibiotics intraoperatively is the key to prevent this complication, but the time, dosage, and choice of the antibiotics are worth discussing. According to the previous work, the investigators found the changes in serum lactate level on postoperative day (POD) 1 could predict postoperative intra-abdominal infection one week before it really happened. The cutoff level of lactate is 3.25mmol/L. Thus, the investigators recommend preventive use of advanced antibiotics for patients who have a peak serum lactate level of \>3.250 mmol/L in 24h after pancreatic resection (doi: 10.1007/s00268-021-05987-8. PMID: 33604712).

The investigators would verify the finding in this randomized controlled trial. Patients with peak lactate level \>3.250 mmol/L in POD1 and met other inclusion criteria would be recruited and separated into "preventive use of advanced antibiotics group" (experimental group) and "routine group" (control group) randomly. Patients in experimental group would be treated with advanced antibiotics to avoid postoperative intra-abdominal infection. Patients in control group would be treated with routine method (antibiotics with lower levels). To compare the incidence rate of infection and other complications, as well as the payment and other index, the investigators would see if the patients in experimental group could have better prognosis after pancreatic surgery.
The present invention discloses a tortoise-tuckahoe food product and a production method thereof. The food product can be prepared into different preparation types. The present invention is characterized in that all traditional Chinese medicine raw materials in the recipe of the tortoise-tuckahoe food product use tortoise shell, tuckahoe, honeysuckle, solomonseal rhizome, angelica, etc. which can be used as medicines and foods and can also be made into health food products. The product has the efficacy of nourishing yin, reducing fever, cooling blood and removing toxicity. The preparation method of the food product of the present invention comprises the steps that the raw materials are added with water to be extracted after being processed; a concentrated solution or a liquid extract is obtained after indiscerptible substances are removed from the mixed solution; the concentrated solution or the liquid extract is respectively made into tortoise-tuckahoe capsules of different flavors and different preparation types, or tablets, or tea liquid beverages, or tortoise-tuckahoe tea granules (solid beverages), or tortoise-tuckahoe cream powder and tortoise-tuckahoe cream, or tortoise-tuckahoe fruit jelly or is respectively made into tortoise-tuckahoe series of food products, such as noodles, biscuits or pastries, or tortoise-tuckahoe ice-cream, or tortoise-tuckahoe sweets, etc. The present invention avoids the problem of food product safety brought by that tortoise-tuckahoe series of food products are prepared by secret recipes and prescriptions in which traditional Chinese medicine raw materials with toxic and side effects are misused.
Introduction: Shoulder pain is one of the most common causes of musculoskeletal complaints found in primary care, with subacromial impact syndrome being the most common. Aging is one of the risk factors for shoulder pain. While psychological factors, which include negative beliefs about pain, catastrophization, kinesiophobia and low self-efficacy, all are related to high levels of pain and disability in the shoulder, predisposing to failure in conservative treatment. Objectives: To verify the effectiveness of pain education added to other treatment modalities (manual therapy and exercises) in the outcomes of pain, functionality, depression, anxiety, stress, kinesiophobia, self-efficacy and strength. Methodology: Randomized controlled clinical trial, which will last for one month of intervention and follow-up for three months. Primary Outcomes: Shoulder Pain and Disability Index Questionnaire that evaluates (pain and disability), Pressure Algometer (pain to pressure) and Visual Analogue Scale (pain). Secondary outcomes: Questionnaire (DASS-21), which evaluates depression, anxiety and stress, Tampa Scale (kinesiophobia), Chronic Pain Self-Efficacy Scale (Self-efficacy) and manual dynamometer that evaluates strength. 74 patients with a diagnosis of subacromial pain, of both sexes, aged between 65 and 85 years will be treated, who will be allocated into two groups: (37 patients for each group). Group A: Manual Therapy + Exercises, individual assistance, twice a week lasting 40 min. (20 min. For each therapy); Group B: Manual Therapy + Exercises + Pain Education, individual care, twice a week lasting 60 min. (20 min. For each therapy. Statistical analysis: The normality distribution will be through the Shapiro-Wilk test. For comparisons of means between and within the groups of outcomes, they will be used using the Generalized Estimation Equations and when necessary , multiple comparisons will be performed using the Bonferroni test, calculated for comparisons between the final and initial moments and initial follow-up in each group: difference in means, 95% confidence interval, effect size (d Cohen). statistical significance adopted will be 5% and the analyzes will be carried out in the statistical programs SPSS 22.0 and R 3.2.4.
The recommendations for leucovorin rescue are based on a methotrexate dose of 12 to 15 grams/m2 administered by intravenous infusion over 4 hours (see methotrexate package insert for full prescribing information). 

Leucovorin rescue at a dose of 15 mg (approximately 10 mg/m2) every 6 hours for 10 doses starts 24 hours after the beginning of the methotrexate infusion. In the presence of gastrointestinal toxicity, nausea or vomiting, leucovorin calcium for injection should be administered parenterally. Do not administer leucovorin calcium for injection intrathecally. 

Serum creatinine and methotrexate levels should be determined at least once daily. Leucovorin calcium for injection administration, hydration, and urinary alkalization (pH of 7.0 or greater) should be continued until the methotrexate level is below 5 x 10-8 M (0.05 micromolar). The leucovorin calcium for injection dose should be adjusted or leucovorin rescue extended based on the following guidelines: 

Patients who experience delayed early methotrexate elimination are likely to develop reversible renal failure. In addition to appropriate leucovorin therapy, these patients require continuing hydration and urinary alkalization, and close monitoring of fluid and electrolyte status, until the serum methotrexate level has fallen to below 0.05 micromolar and the renal failure has resolved. 

Some patients will have abnormalities in methotrexate elimination or renal function following methotrexate administration, which are significant but less severe than abnormalities described in the table above. These abnormalities may or may not be associated with significant clinical toxicity. If significant clinical toxicity is observed, leucovorin rescue should be extended for an additional 24 hours (total of 14 doses over 84 hours) in subsequent courses of therapy. The possibility that the patient is taking other medications which interact with methotrexate (e.g., medications which may interfere with methotrexate elimination or binding to serum albumin) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed.
<P>PROBLEM TO BE SOLVED: To provide a hair treatment composition facilitating the inhibition of the occurrence of unpleasant hardness in the hair when repairing a damaged hair protein with an ampholytic polymer compound, and to provide a method of hair treatment.  <P>SOLUTION: The hair treatment composition contains (A) the ampholytic polymer compound and (B) a diester. The hair treatment composition contains a polymer of monomers containing a cationic monomer, an anionic monomer and a nonionic monomer as the ampholytic polymer compound (A). The diester (B) is a diester of cyclohexane-1,4-dicarboxylic acid with polyoxyethylene alkyl ethers. The hair treatment composition preferably contains (C) amino acids besides them. The method of the hair treatment using the hair treatment composition includes subjecting the hair to hairdye treatment by coating a hairdye composition on the hair after applying the hair treatment composition to the hair.  <P>COPYRIGHT: (C)2010,JPO&INPIT
BACKGROUND: Adenocarcinoma in situ (AIS) of the cervix can progress to invasive adenocarcinoma. While hysterectomy is standard, conservative management may be considered for women desiring future pregnancies. This study aimed to determine the prevalence of residual disease in hysterectomy specimens following excisional therapy with clear margins for AIS.
METHODS: A retrospective FRANCOGYN cohort study was conducted on patients who underwent a hysterectomy after conization with clear margins for AIS between 2008 and 2021. The primary goal was to assess the prevalence of residual disease in the hysterectomy specimens. Secondary objectives included identifying preoperative predictors of residual disease and comparing recurrence rates between patients with and without residual disease.
RESULTS: Of 53 hysterectomies performed after conization with negative margins for AIS, 20.8% (11/53) showed residual disease in the final histology. None of the patients had invasive cancer. In the residual disease group, 18% (2/11) had persistent CIN 3, and 82% (9/11) had persistent AIS. These patients tended to have higher BMI (27.5 kg/m² vs. 23.6 kg/m², p=0.04) and shorter endocervical margins (2mm vs. 5mm, p=0.01). No recurrences were observed during follow-up.
CONCLUSION: Despite clear margins on the initial conization for AIS, 20% of patients had residual disease in their hysterectomy samples, though no invasive cancer was found. A hysterectomy should be considered after completing childbearing, even if initial margins are clear.
RATIONALE: Myocardial fibrosis is an important pathological change that occurs during ventricular remodeling in patients with hypertension and is an important pathophysiological basis of cardiovascular disease. However, the molecular mechanism underlying this ventricular remodeling is unclear.
METHODS: Bioinformatics analysis identified HLA-B and TIMP1 as hub genes in the process of myocardial fibrosis. Expression and correlation analyses of significant hub genes with ventricular remodeling were performed. Weighted gene co-expression network analysis (WGCNA) was performed to verify the role of HLA-B. ceRNA network was constructed to identify the candidate molecule drugs. Receiver operating characteristic (ROC) curves were analyzed.
RESULTS: RT-qPCR was performed to verify the roles of HLA-B and TIMP1 in seven control individuals with hypertension and seven patients with hypertension and ventricular remodeling. The WGCNA showed that HLA-B was in the brown module and the correlation coefficient between HLA-B and ventricular remodeling was 0.67. Based on univariate logistic proportional regression analysis, HLA-B influences ventricular remodeling (P<0.05). RT-qPCR showed that the relative expression levels of HLA-B and TIMP1 were significantly higher in HLVR samples compared with their expression in the control group.
CONCLUSIONS: HLA-B and TIMP1 might provide novel research targets for the diagnosis and treatment of HLVR.
Osteopathic manipulative medicine (OMM) is a well-researched standard of care in the treatment of low back pain (LBP). Under the heading of OMM, many different modalities exist to decrease a patient's somatic dysfunction. Among the most commonly used are high velocity (thrusting through an immobilized joint) and muscle energy (engaging a restrictive barrier using the patient's own strength).

Although a very common complaint, there is no exact etiology for LBP. Many different theories exist, including postural disturbances, leg length discrepancies, and even genetic predispositions. A study in Spine finds that among those with chronic LBP there is a subgroup of people with reduced hip flexion, and concludes that hip motion should be considered in treatment of patients with LBP. Currently, there exists no research on the manipulation of hip flexors in the treatment of LBP. This study, therefore, will test the efficacy of OMM on the deep pelvic musculature as a way of decreasing LBP.
Despite the effectiveness of oral contraceptives, pregnancy rates are high among women who choose this method of birth control. These pregnancies occur due to incorrect use, premature discontinuation, and failure to begin taking oral contraceptives after they have been prescribed. As many as 25% of adolescents who seek oral contraceptives from family planning clinics never take the first pill. Failure to begin oral contraceptives may occur due to ambivalence, confusion about starting instructions, or intervening pregnancy. Conventional starting instructions for oral contraceptives require waiting until the next menstrual period; this may leave the woman at high risk of pregnancy. This trial will evaluate a "quick start" approach in which the woman swallows the first pill during the clinic visit under direct observation and then continues daily pill use without waiting for her next menses. The trial will determine whether immediate oral contraceptive initiation offers benefits compared to conventional starting approaches.

Participants in this study will be randomized to receive either the quick start or the standard starting approach. Participants will complete a questionnaire at study entry and Months 3 and 6. The main outcomes are 6-month oral contraceptive continuation rates and pregnancy rates.
Kegel exercises will be performed by the researcher within the first 8 hours after being taken to the clinic room to perform the Kegel pelvic floor muscle exercises while in the supine position. Urinary retention and comfort level of patients will be evaluated after surgery.
Ferroptosis plays an essential role in the pathological progression of hepatic ischemia-reperfusion injury (HIRI), which is closely related to iron-dependent lipid peroxidation. Since mitochondria are thought to be the major site of reactive oxygen species (ROS) production and iron storage, monitoring the variations of mitochondrial hypochlorous acid (HClO) (an important member of ROS) has important implications for the assessment of ferroptosis status, as well as the formulation of treatment strategies for HIRI. However, reliable imaging tools for the visualization of mitochondrial HClO and monitoring its dynamic changes in ferroptosis-mediated HIRI are still lacking. Herein, in this work, an HClO-activated near-infrared (NIR) cyclometalated iridium(III) complex-based probe, named NIR-Ir-HClO, was developed for the visual monitoring of the mitochondrial HClO fluxes in ferroptosis-mediated HIRI. The newly prepared probe showed fast response (<30 s), good sensitivity, excellent selectivity, good cell biocompatibility, and satisfactory mitochondrial-targeting performance, making it suitable for accurate monitoring of mitochondrial HClO in living cells. Moreover, visualization of the variations of mitochondrial HClO in ferroptosis-mediated HIRI and monitoring of the treatment response of ferroptosis-mediated HIRI to the ferroptosis inhibitors were achieved for the first time. All these show that probe NIR-Ir-HClO can be utilized as a reliable imaging tool for revealing the pathological mechanism of mitochondrial HClO in ferroptosis-mediated HIRI, as well as for the formulation of new treatment strategies for HIRI.
Patients receive pBI-11 vaccine IM, TA-HPV vaccine IM, and pembrolizumab IV on study. Patients undergo CT or MRI and blood sample collection during screening and on study. Patients may undergo tumor biopsy during screening and on study.
The invention discloses a system. The disclosed system calculates a single score for a consumer product that indicates the nutritional health of the consumer product. In one embodiment, nutritional health is based on recommended calorie intake, indicating whether nutrients within the consumer product are within a user-specific health range. The system determines the impact on the nutritional health of an individual by determining whether the nutritional content of the consumer product falls within a range tailored to the individual. The range may be calculated, for example, using a plurality of possible minimum intake values and upper limits (if any) for each nutrient. In one embodiment, the system particularly emphasizes the effect when the consumption of the nutrient is negative beyond a pair of endpoints that define a healthy consumption of the nutrient.
1,158,169. Magnesium hydroxide suspensions. COLGATE-PALMOLIVE CO. 7 April, 1967 [12 April, 1966], No. 16108/67. Heading A5B. Antacid and laxative stable aqueous suspensions, comprising powdered magnesium hydroxide in an amount of from 65 to 90 grams per litre of the suspension and carboxymethyl cellulose or an alkali metal salt thereof (e.g. sodium) in an amount of from 0.16 to 0.77 gram per gram of magnesium hydroxide or in an amount of from 15 to 50 grams per litre of the suspension, are prepared by dispersing the carboxymethyl cellulose in water, heating the dispersion to from 45‹ to 90‹C., maintaining the dispersion in this temperature range for at least 30 mins. (e.g. approximately one hour), cooling the dispersion substantially to ambient temperature, adding magnesium hydroxide powder to the dispersion, adding additional water to the dispersion in an amount to reduce the concentration of magnesium hydroxide in the dispersion to from 65 to 90 grams per litre of the dispersion, continuously stirring the dispersion from the incorporation of the carboxymethyl cellulose until after the addition of the additional water, homogenizing the dispersion after the addition of the additional water, and enclosing the dispersion in a container protected from the atmosphere. The suspension may also contain a flavouring agent (e.g. calcium cyclamate, sodium saccharin, vanilla extract or a mixture thereof), which may be added to the dispersion after the cooling and prior to addition of the magnesium hydroxide. The dispersion of carboxymethyl cellulose in water may be made using all the carboxymethyl cellulose and from 50 to 60% of the water to be used in the suspension.
Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
Current virus vaccines made of inactivated particles often induce undesirable local and general secondary reactions. Therefore there is a need for a vaccine that would not contain the substances responsible for these side effects. An immunosome has been constructed, highly immunogenic, which is exclusively made of the antigens attached onto the membrane of a preformed liposome. This immunosome is prepared by providing a quantity of preformed liposomes; providing an antigen viral sub-unit-detergent complex; treating the preformed liposomes to enable antigen sub-units to anchor onto the liposomes so as to form projections on the outer surface of said liposomes; and combining said antigen viral sub-unit-detergent complex with the liposomes obtained above so as to give said immunosomes. This technique recreates a structure that is almost undistinguishable from the virus particle. This immunosome is more immunogenic than the subunits used for its preparation.
In the laparoscopic salpingo-oophorectomy, after the induction of anesthesia, an umbilical skin incision was performed. Pneumoperitoneum was established using dry, nonheated CO2 insufflation through a Veress needle. A 10-mm trocar was inserted into the abdominal cavity through the umbilical incision for the laparoscope. Subsequently, three 5-mm ancillary trocars, 2 on the lower abdominal quadrants and 1 on the left upper quadrant, were introduced to the abdominal space under direct optic visualization. IAP was set at 14 mm Hg and maintained with a gas insufflator (Endoflator; Karl Storz Endoscopy, Tuttlingen, Germany)Immediately after the port placement, unilateral oophorectomy was performed, and ovarian biopsies were obtained. The operation continued with ligation and transection of the contralateral utero-ovarian ligament and the bilateral round ligaments. The contralateral infundibulopelvic ligament, which contains the main vascular supply for the contralateral ovary, remained intact. Subsequently, anterior and posterior leaflets of the broad ligament were identified and dissected, and the bladder was placed away from the lower uterine segment. The uterus removed from vaginal way after necessary steps. After desufflation, the cuff closure procedure was performed vaginally. At the end of the closure, pneumoperitoneum was reestablished, the remaining contralateral ovary was removed immediately, and biopsies were obtained for histologic analyses.
Patients receive rituximab IV, bevacizumab IV over 30-90 minutes, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1. Patients also receive oral prednisone on days 1-5. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
The invention relates to a novel cosmetic product with special flexibility and stretching characteristics, so-called "stretch-mascara". The mascara has an oil phase and an aqueous phase, said oil phase containing 2 to 10 wt. % of an unbranched polyethylene wax with a molecular weight of 400 to 1500 Dalton, in relation to the weight of the oil phase, and at least one other wax or oil or mixture thereof. The aqueous phase contains 0.5 to 5 % of a film former PVP/PVP-VA, polyquaternium-46 and mixtures thereof. The product also contains 0.5 to 20 wt. % of an external film former phase with a water-soluble film former selected from the group PEG/PPG-25/25 dimethicone/acrylates/t-butyl acrylates copolymer, polyurethane-1 and mixtures thereof.
Each enrolled participant in a single arm will be offered a virtual reality headset with a menu of virtual reality environments and experiences such as nature scenes, mindful meditation, travel, and various games. Enrolled participants be offered the virtual reality as early as the first day after their inpatient surgery in their hospital room. Each virtual reality session will last 5-30 minutes, depending on the participant's selection of the virtual reality environment/experience. Participants will have the option to use the virtual reality as often as twice daily up through the third day after their surgery during their hospitalization, for a total of six sessions.
The composition and the method find application in medical practice. The composition has good physico-mechanical and biopharmaceutical characteristics - decomposition, tolerance and high stability. It is administered orally. It comprises from 480 to 550 mg magnesium - DL-aspartate.4H20 and auxiliary substances, such as wheat starch, colidon VA-64, crospovidon, magnesium stearate, talcum, microcrystalline cellulose and gelatine. It is produced after granulation of a mixture of magnesium-bis-DL-aspartate and wheat starch in aqueous solution of gelatine. The granulate is dried and calibrated, after which it is mixed with the remaining auxiliary substances and is tablet-formed at average weight per tablet in mg 0.720( 5%. 2 claims